ADDIS ABABA – The World Health Organization issued an emergency use listing (EUL) for Nuvaxovid™, expanding the basket of WHO-validated vaccines against the SARS-CoV-2 virus to 10.
The UN agency approved the vaccine following its assessment and approval by the European Medicines Agency (EMA) on Tuesday.
The new vaccine was developed by Novavax and the Coalition for Epidemic Preparedness Innovations (CEPI), and is the originator product for the Covovax™ vaccine that received WHO emergency use listing on 17 December.
Both vaccines are made using the same technologies.
They require two doses and are stable at 2 to 8 °C refrigerated temperatures, according to the UN health agency.
WHO’s Strategic Advisory Group of Experts on Immunization has also issued policy recommendations for Nuvaxovid™/Covovax™.
The objective is to make medicines, vaccines and diagnostics available as rapidly as possible to address the emergency while adhering to stringent criteria of safety, efficacy and quality, according to their export.
The assessment, they say, weighs the threat posed by the emergency as well as the benefit that would accrue from the use of the product against any potential risks.